What is the purpose of this study?NADPH oxidase 2 (NOX2) is the isoform of NOX found in phagocytes including neutrophils, NOX2 activation generates reactive oxygen species (ROS) with antimicrobial activities. Patients with advanced alcoholic cirrhosis or alcoholic hepatitis are more susceptible to infections due to deficient ROS production by neutrophils. The primary aim of this study is to see if ROS production by neutrophils is attributed to reduced NOX2 activity in neutrophils amongst these patients which cause them to be more susceptible to infections. THIS STUDY IS ENROLLING BY INVITATION ONLY - Our recruitment process for cases consists of screening patients weekly that have appointments in the DaLD Liver Clinic at IU Hospital by reviewing their medical records to see if they fit the eligibility/ineligibility criteria listed in the protocol. If they do, it is sent to the PI for further review and if the PI confirms then the patient will be approached at their liver appointment in their exam room while waiting to see the doctor or right after they have been seen. Controls will be recruited by flyer, they will be contacting us after seeing flyer and then determined eligibility will conducted and if they are we will schedule an appointment with them to be seen in a reserved research room.

What is the purpose of this study?The purpose of this ancillary study to the iGDM randomized clinical trail is to determine whether CGM can reveal additional information about maternal glucose values above and beyond the information obtained from checking blood glucose values 4 times per day. THIS STUDY IS ENROLLING BY INVITATION ONLY - Participants who enroll in the iGDM study will be identified as eligible for CGM for iGDM, and these participants will be assessed for interest following enrollment in iGDM. Recruitment for the study will occur telephonically, through email, and in-person depending on method of iGDM recruitment and/or participant preference. Study coordinators will verbally provide information regarding CGM for iGDM if a potential participant expresses interest in the study.

What is the purpose of this study?This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging.Primary: To describe the safety of 68Ga-R10602.Secondary - To describe the biodistribution of 68Ga-R10602 in Study Participants with hormone receptor-positive breast cancer. - To describe organ and whole-body dosimetry of 68Ga-R10602. - To describe the pharmacokinetic (PK) profile of 68Ga-R10602. - To compare 68Ga-R10602 positron emission tomography/computed tomography (PET/CT) scans to standard of care imaging (e.g. contrast-enhanced diagnostic CT images) in detecting tumor lesions in Study Participants with breast cancer. - To describe image quality at simulated lower administered radioactivity of 68Ga-R10602.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632</div>

What is the purpose of this study?The purpose of this study is to learn more about the impact of a substance use disorder (SUD) Integrated Behavioral Health Program (IBH) on primary care providers (PCPs) willingness to engage in and views/attitudes around adolescent SUD treatment as well as IBH team dynamics.  THIS STUDY IS ENROLLING BY INVITATION ONLY - Eligible participants include all IUH employees at primary care clinics participating in IBH, including primary care providers and pediatricians, psychiatrists, psychologists, LMHCs, therapists, service line administrators, strategy staff, and representatives from Riley Childrens Foundation. Eligible participants must have some role in the implementation or sustainability of IBH. PIUH employee participants will be invited by email - using comprehensive clinic staff contact lists - to attend a presentation on the study in large forum settings (e.g., regular staff meetings), with multiple clinic staff members learning about the study at the same time. Potential participants will recieve an opportunity to participate in the surveys over email, such that enrollment into the study (i.e., survey participation) will occur on the staff members' own time and at a location where they can respond to survey questions.

What is the purpose of this study?The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy.Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy.The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy.Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632</div>

What is the purpose of this study?This study aims to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIC to IVA cervical cancer with lymph node involvement) who have not progressed following platinum-based CCRT. THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632</div>